+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience



Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience



Zhonghua Zhong Liu Za Zhi 35(2): 144-147



To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC). From January 2006 to March 2010, sixty-two HCC patients were randomly treated with RFA combined with TACE (n = 32) or RFA alone (n = 30). This group included the patients who had Child-Pugh class A or B with three or fewer tumors, in which just one tumor size was 3 - 5 cm in diameter, and no evidence of extrahepatic tumor metastasis or macrovascular invasion. The follow up ranged from 9 to 39 months. Survival probabilities were estimated with the Kaplan-Meier method, and differences between survival curves were evaluated with the Log rank test. At the end of the study, the 1-, 2- and 3-year overall survival rates in the combined treatment group were 90.6%, 72%, and 53.1%, respectively, and in the radiofrequency ablation alone group were 83.3%, 56.75%, and 23.3%, respectively. The differences between the survival curves of the two groups were not statistically significant (P = 0.176). The 1-, 2-, and 3-year progress-free survival rates in the combined treatment group were 75.0%, 50.0%, and 34.3%, respectively, and in the radiofrequency ablation alone group were 63.3%, 33.3%, and 16.7%, respectively. The differences between the two groups were statistically significant (P = 0.027). The 1-, 2-, and 3-year local tumor progression rates in the combined treatment group were 12.5%, 18.75%, and 18.75% vs. 16.7%, 30%, and 36.6% in the radiofrequency ablation alone group, with a significant difference between the two groups (P = 0.047). Radiofrequency ablation plus TACE is better than radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052125094

Download citation: RISBibTeXText

PMID: 23714672


Related references

Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean Journal of Radiology 14(4): 626-635, 2014

Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chinese Journal of Cancer Research 26(1): 112-118, 2014

Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?. Yearbook of Diagnostic Radiology 2010: 290-293, 2010

Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 252(3): 905-913, 2009

Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (Tace) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) for Treatment of Intermediate Hepatocellular Carcinoma. Gastroenterology 144(5): S-722, 2013

P.13.7 Comparison Between Transcatheter Arterial Chemoembolization (Tace) And Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) For Treatment Of Intermediate Hepatocellular Carcinoma (Hcc). Digestive and Liver Disease 45: S183-S184, 2013

Quality of Life after Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison with Transcatheter Arterial Chemoembolization Alone. Quality of Life Research 16(3): 389-397, 2007

Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Quality of Life Research 16(3): 389-397, 2006

Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. Oncology 84 Suppl 1: 40-43, 2013

Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone-beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma. Asian Pacific Journal of Cancer Prevention 14(3): 1649-1654, 2014

Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm. Asia-Pacific Journal of Clinical Oncology 2017, 2017

Transcatheter arterial chemoembolization combined with immediate radiofrequency ablation for the treatment of large hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 95(27): 2170-2173, 2016

Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Digestive and Liver Disease 47(3): 242-248, 2015

Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided radiofrequency ablation in the treatment of solitary large hepatocellular carcinoma. La Radiologia Medica 2018, 2018

Clinical value of (125)I radioactive seed implantation plus transcatheter arterial chemoembolization combined with radiofrequency ablation in treating patient with sub-capsular hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 98(47): 3853-3857, 2018